ClinicalTrials.gg
Active, not recruitingNCT05566795Updated Oct 19, 2026

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

A Phase 3 interventional study of Tovorafenib and Chemotherapeutic Agent in Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma and Pediatric Low-grade Glioma, sponsored by Day One Biopharmaceuticals, Inc.. Active, not recruiting at 138 sites in 30 countries. Open to participants aged Up to 25 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Day One Biopharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Updated Oct 19, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
418
Allocation
Randomized
Ages
Up to 25 Years
Sex
All
01

Study summary

This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring first-line systemic therapy.

Read the detailed description

Approximately 400 treatment-naïve LGG participants will be randomized 1:1 to either tovorafenib (Arm 1) or an Investigator's choice of SoC chemotherapy (Arm 2).

Arm 1 (tovorafenib): Treatment cycles will repeat every 28 days in the absence of disease progression. Participants will continue tovorafenib until any of the following occurs: disease progression, unacceptable toxicity, withdrawal of consent to treatment, or end of study.

Arm 2 (Investigator's Choice of SoC Chemotherapy): Participants will receive one of 4 SoC chemotherapy options selected by the treating Investigator: Children's Oncology Group - Vincristine/Carboplatin (COG-V/C) regimen, International Society for Paediatric Oncology - Low-Grade Glioma Vincristine/Carboplatin (SIOPe-LGG-V/C) regimen, vinblastine (VBL) regimen, or monthly carboplatin. The choice of SoC chemotherapy regimen will be selected prior to participant randomization. Treatment will continue until completion of therapy or until any of the following occurs: disease progression, unacceptable toxicity, withdrawal of consent to treatment, or end of study.

Participants who discontinue treatment due to disease progression will have (1) radiographic evidence of disease progression, as determined by the Investigator, or (2) clinical progression, as determined by the Investigator. Investigators are encouraged to discuss cases of clinical progression and early radiographic progression without clinical symptoms with the Sponsor Medical Monitor prior to treatment discontinuation or initiation of a different form of treatment for the malignancy. Participants may continue therapy beyond progressive disease (PD).

02

Conditions studied

  • Low-grade Glioma
  • Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma
  • Pediatric Low-grade Glioma

Keywords

  • Rapidly accelerated fibrosarcoma
  • RAF alteration glioma
  • Glioneural tumor
  • Ojemda
03

In context

Lead sponsor

Day One Biopharmaceuticals, Inc. is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 19, 2026. See what changed

Ages eligible
Up to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Less than 25 years of age with LGG harboring a documented known activating RAF alteration, as identified through molecular assays performed at Clinical Laboratory Improvement Amendments (CLIA) or other similarly certified laboratories.
  • Histopathologic diagnosis of glioma or glioneuronal tumor.
  • At least one measurable T2/FLAIR lesion that can be reproducibly measured in at least 2 dimensions of at least 10 millimetres (mm), visible on 2 or more axial slices that are preferably, at most, 5 mm apart with 0-mm skip.
  • Meet indication for systemic therapy.

Exclusion criteria

Exclusion Criteria:

  • Participant has any of the following tumor-histological findings:

    1. Schwannoma
    2. Subependymal giant cell astrocytoma (Tuberous Sclerosis)
    3. Diffuse intrinsic pontine glioma, even if diagnosed as World Health Organization (WHO) Grade I-II
  • Participant's tumor has additional pathogenic molecular alterations, (even if histologically low-grade) including but not limited to any of the following: a) isocitrate dehydrogenase (IDH) 1/2 mutation, b) Histone H3 mutation, and c) neurofibromatosis Type 1 (NF-1) loss of function alteration.
  • Known or suspected diagnosis of NF-1/ neurofibromatosis Type 2 (NF-2) via genetic testing or current diagnostic clinical criteria.
  • Prior or ongoing nonsurgical anticancer therapy for this indication (eg, chemotherapy, oral/IV targeted therapy) including radiation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
418 participants (actual)

Study arms

  • Experimental
    Tovorafenib

    Drug: Tovorafenib

  • Active comparator
    Investigator's choice of Standard of care therapy

    Drug: Chemotherapeutic Agent

Interventions

  • Oral Tablet Powder for Oral Suspension

    Also known as: DAY101, Ojemda

  • DrugChemotherapeutic Agent

    Intravenous solution for injection

    Also known as: COG-V/C, SIOPe-LGG-V/C, VBL, Carboplatin

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) of tovorafenib monotherapy versus SoC chemotherapy

    ORR assessed per Response Assessment in Pediatric Neuro Oncology (RAPNO) criteria by Independent Review Committee (IRC), and defined as the proportion of participants with overall confirmed response of complete response (CR), partial response (PR), or minor response (MR).

    Time frame: Up to 60 months

Secondary outcomes

  1. Progression-free survival (PFS) of tovorafenib monotherapy versus SoC chemotherapy

    PFS assessed per RAPNO criteria by IRC, and defined as time from randomization to PD or death from any cause, whichever comes first.

    Time frame: Up to 60 months

  2. Event-free survival (EFS) of tovorafenib monotherapy versus SoC chemotherapy

    EFS assessed per RAPNO criteria by IRC, defined as time from randomization to PD, death from any cause, or initiation of any new anticancer therapy, whichever comes first.

    Time frame: Up to 60 months

  3. Time to next treatment (TTNT) of tovorafenib monotherapy versus SoC chemotherapy

    Time to next treatment is defined as time from randomization to initiation of any new anticancer treatment or death from any cause, whichever occurs first.

    Time frame: Up to 60 months

  4. Overall survival (OS) of tovorafenib monotherapy versus SoC chemotherapy

    Overall survival is defined as time from randomization up to death from any cause.

    Time frame: Up to 60 months

07

Study locations

138 sites

Showing the first 100 of 138 sites across 30 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Amayiri N, Mushtaq N, Ghalibafian M, Bouffet E. Management of pediatric brain tumors in low- and middle-income countries. Adv Cancer Res. 2025;167:427-453. doi: 10.1016/bs.acr.2025.08.004. Epub 2025 Sep 9. PubMed 41198344 ↗
  • van Tilburg CM, Kilburn LB, Perreault S, Schmidt R, Azizi AA, Cruz-Martinez O, Zapotocky M, Scheinemann K, Meeteren AYNS, Sehested A, Opocher E, Driever PH, Avula S, Ziegler DS, Capper D, Koch A, Sahm F, Qiu J, Tsao LP, Blackman SC, Manley P, Milde T, Witt R, Jones DTW, Hargrave D, Witt O. LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration. BMC Cancer. 2024 Jan 30;24(1):147. doi: 10.1186/s12885-024-11820-x. PubMed 38291372 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2023 (actual). Primary completion is estimated for Jun 2027, 52 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2022
First posted
Oct 4, 2022
StartActual
Feb 27, 2023
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2031
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited, 1 added, 1 removed; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedLess than 25 years of age with LGG withharboring a documented known activating RAF alteration, as identified through molecular assays performed at Clinical Laboratory Improvement Amendments (CLIA) or other similarly certified laboratories.
  • RemovedAt least one measurable lesion as defined by RANO criteria.
  • AddedAt least one measurable T2/FLAIR lesion that can be reproducibly measured in at least 2 dimensions of at least 10 millimetres (mm), visible on 2 or more axial slices that are preferably, at most, 5 mm apart with 0-mm skip.
Exclusion criteria
  • EditedParticipant's tumor has additional pathogenic molecular alterations, (even if histologically low-grade) including but not limited to any of the following: a) isocitrate dehydrogenase (IDH) 1/2 mutation, b) Histone H3 mutation, and c) neurofibromatosis Type 1 (NF-1) loss of function alteration.
  • EditedKnown or suspected diagnosis of NF-1/ neurofibromatosis Type 2 (NF-2) via genetic testing or current diagnostic clinical criteria.
Oct 19, 2026
Secondary outcomes
1 edited, 16 removed
What changed in the outcomes
  • EditedChange from baseline in Adaptive Behavior Composite ScoreTime to next treatment (ABSTTNT) of tovorafenib monotherapy versus SoC chemotherapyTime frame: Baseline, Year 1, 2 and 5 → Up to 60 months
  • RemovedNumber of participants with any treatment-emergent adverse events, and Serious adverse eventsTime frame: Up to 60 months
  • Removed. Number of participants with clinically significant vital signs and laboratory abnormalities findingsTime frame: Up to 60 months
  • RemovedChange from baseline in the Motor Skills Domain Score of tovorafenib monotherapy versus SoC chemotherapyTime frame: Baseline, Year 1, 2 and 5
  • RemovedChange from baseline in the Daily Living Domain Score of tovorafenib monotherapy versus SoC chemotherapyTime frame: Baseline, Year 1, 2 and 5
  • RemovedChange from baseline in the Communication Domain Score of tovorafenib monotherapy versus SoC chemotherapyTime frame: Baseline, Year 1, 2 and 5
  • RemovedChange from baseline in the Socialization Domain Score of tovorafenib monotherapy versus SoC chemotherapyTime frame: Baseline, Year 1, 2 and 5
  • RemovedChange in age-adjusted visual acuity (VA) of tovorafenib monotherapy versus SoC chemotherapy in optic pathway glioma (OPG) participants aged < 3 yearsTime frame: Baseline and up to 5 years
  • RemovedChange in best corrected visual acuity of tovorafenib monotherapy versus SoC chemotherapy in OPG participants aged ≥ 3 yearsTime frame: Baseline and up to 5 years
  • RemovedVisual progression-free survival (v-PFS) of tovorafenib monotherapy versus SoC chemotherapyTime frame: Up to 60 months
  • RemovedORR of tovorafenib monotherapy versus SoC chemotherapyTime frame: Up to 60 months
  • RemovedClinical benefit rate (CBR) of tovorafenib monotherapy versus SoC chemotherapyTime frame: Up to 60 months
  • RemovedTime to response (TTR) of tovorafenib monotherapy versus SoC chemotherapyTime frame: Up to 60 months
  • RemovedPFS of tovorafenib monotherapy versus SoC chemotherapyTime frame: Up to 60 months
  • RemovedEFS of tovorafenib monotherapy versus SoC chemotherapyTime frame: Up to 60 months
  • RemovedDuration of response (DOR) of tovorafenib monotherapy versus SoC chemotherapyTime frame: Up to 60 months
  • RemovedChange from Baseline in health-related quality of life (HRQoL) total score of tovorafenib monotherapy versus SoC chemotherapyTime frame: Baseline, Year 1, 2 and 5
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Eligibility 1 inclusion criterion edited, 1 added, 1 removed; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedLess than 25 years of age with LGG withharboring a documented known activating RAF alteration, as identified through molecular assays performed at Clinical Laboratory Improvement Amendments (CLIA) or other similarly certified laboratories.
    • RemovedAt least one measurable lesion as defined by RANO criteria.
    • AddedAt least one measurable T2/FLAIR lesion that can be reproducibly measured in at least 2 dimensions of at least 10 millimetres (mm), visible on 2 or more axial slices that are preferably, at most, 5 mm apart with 0-mm skip.
    Exclusion criteria
    • EditedParticipant's tumor has additional pathogenic molecular alterations, (even if histologically low-grade) including but not limited to any of the following: a) isocitrate dehydrogenase (IDH) 1/2 mutation, b) Histone H3 mutation, and c) neurofibromatosis Type 1 (NF-1) loss of function alteration.
    • EditedKnown or suspected diagnosis of NF-1/ neurofibromatosis Type 2 (NF-2) via genetic testing or current diagnostic clinical criteria.
    Secondary outcomes 1 edited, 16 removed
    What changed in the outcomes
    • EditedChange from baseline in Adaptive Behavior Composite ScoreTime to next treatment (ABSTTNT) of tovorafenib monotherapy versus SoC chemotherapyTime frame: Baseline, Year 1, 2 and 5 → Up to 60 months
    • RemovedNumber of participants with any treatment-emergent adverse events, and Serious adverse eventsTime frame: Up to 60 months
    • Removed. Number of participants with clinically significant vital signs and laboratory abnormalities findingsTime frame: Up to 60 months
    • RemovedChange from baseline in the Motor Skills Domain Score of tovorafenib monotherapy versus SoC chemotherapyTime frame: Baseline, Year 1, 2 and 5
    • RemovedChange from baseline in the Daily Living Domain Score of tovorafenib monotherapy versus SoC chemotherapyTime frame: Baseline, Year 1, 2 and 5
    • RemovedChange from baseline in the Communication Domain Score of tovorafenib monotherapy versus SoC chemotherapyTime frame: Baseline, Year 1, 2 and 5
    • RemovedChange from baseline in the Socialization Domain Score of tovorafenib monotherapy versus SoC chemotherapyTime frame: Baseline, Year 1, 2 and 5
    • RemovedChange in age-adjusted visual acuity (VA) of tovorafenib monotherapy versus SoC chemotherapy in optic pathway glioma (OPG) participants aged < 3 yearsTime frame: Baseline and up to 5 years
    • RemovedChange in best corrected visual acuity of tovorafenib monotherapy versus SoC chemotherapy in OPG participants aged ≥ 3 yearsTime frame: Baseline and up to 5 years
    • RemovedVisual progression-free survival (v-PFS) of tovorafenib monotherapy versus SoC chemotherapyTime frame: Up to 60 months
    • RemovedORR of tovorafenib monotherapy versus SoC chemotherapyTime frame: Up to 60 months
    • RemovedClinical benefit rate (CBR) of tovorafenib monotherapy versus SoC chemotherapyTime frame: Up to 60 months
    • RemovedTime to response (TTR) of tovorafenib monotherapy versus SoC chemotherapyTime frame: Up to 60 months
    • RemovedPFS of tovorafenib monotherapy versus SoC chemotherapyTime frame: Up to 60 months
    • RemovedEFS of tovorafenib monotherapy versus SoC chemotherapyTime frame: Up to 60 months
    • RemovedDuration of response (DOR) of tovorafenib monotherapy versus SoC chemotherapyTime frame: Up to 60 months
    • RemovedChange from Baseline in health-related quality of life (HRQoL) total score of tovorafenib monotherapy versus SoC chemotherapyTime frame: Baseline, Year 1, 2 and 5
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05566795
Lead sponsor
Day One Biopharmaceuticals, Inc.
Collaborators
SIOPe Brain Tumor Group LOGGIC Consortium
Responsible party
Sponsor
First posted
Oct 4, 2022
Start date
Feb 27, 2023
Primary completion
Jun 2027 (estimated)
Completion
Jun 2031 (estimated)
Last update
Oct 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tovorafenib

Start the discussion